PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
BESREMi® is a next-generation interferon approved for the treatment of adults with PV
PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that its wholly owned subsidiary, FORUS Therapeutics Inc, has received a Notice of Compliance (NOC) authorizing BESREMi® (ropeginterferon alfa-2b) for the treatment of adults with polycythemia vera (PV). BESREMi® is expected to become commercially available in Canada in the coming weeks.
PV is a rare, chronic blood cancer characterized by overproduction of red blood cells, which increases blood viscosity and can lead to serious complications, including thrombosis, stroke, myocardial infarction, and progression to myelofibrosis or acute myeloid leukemia.
“We are very pleased that Health Canada has approved BESREMi® for the treatment of adults with PV,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. “BESREMi® is a next-generation interferon demonstrated to provide durable hematologic and molecular responses, reduced symptom burden, and a favorable safety and tolerability profile. We look forward to working closely with Canadian hematologists and other key stakeholders to make BESREMi® available to patients living with PV across Canada.”
